This study is in progress, not accepting new patients
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Prostate cancer, Abiraterone Acetate (ZYTIGA), Prednisone, JNJ-56021927, Abiraterone Acetate
Lead Scientist at UCSF
- Terence Friedlander
I am a clinical and translational medical oncologist with a focused on urologic cancers, specifically cancers of the bladder, prostate, and kidney. I am also the Chief of the ZSFG Division of Hematology and Oncology. My research is focused on understanding the basic biology of urologic and other malignancies and in developing novel therapeutic ways to treat disease.
- in progress, not accepting new patients
- Start Date
- Completion Date
- Aragon Pharmaceuticals, Inc.
- Phase 1 research study
- Study Type
- About 57 people participating
- Last Updated